A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, ...
A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, ...
A UK study of more than 165,000 dementia patients has found that an anti-psychotic medication called Risperidone raises ...
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive ...
Risperidone raises stroke risk without exception in patients with dementia, say researchers who analysed GP records.
The FDA has approved risperidone once-monthly, extended-release injectable suspension for maintenance treatment of bipolar I ...
GlobalData on MSN
FDA approves Teva and Medincell’s bipolar I disorder treatment
The approval is supported by a combination of current clinical data and model-informed drug development techniques.
Zacks Investment Research on MSN
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva Pharmaceutical Industries Limited TEVA recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone). The regulatory body has now approved Uzedy (50 mg, 75 ...
March 24, 2010 — One year of maintenance risperidone administered at the initial therapeutic dose for acute schizophrenia is more effective at preventing relapse than dose reduction strategies and is ...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback